• Dinobandhu Nandi Department of Medical Laboratory Science School of Physiotherapy and Paramedical Sciences, Lovely Professional University, Phagwara, Punjab, India
  • Anania Arjuna Department of Medical Laboratory Science School of Physiotherapy and Paramedical Sciences, Lovely Professional University, Phagwara, Punjab, India



HAI, Acinetobacter baumannii, Nil, VAP


Hospital acquired infections (HAIs) are mostly caused by Gram-negative organisms and is one of the major issues in patient safety. These infections
are often associated with the medical processes of hospitals such as invasive medical devices and various surgical procedures. Gram-negative
organisms account for most infections in the hospital environment because of their ability to acquire resistant against multiple antibiotics. Through
different mechanisms including the synthesis of β- lactamases, overexpression of transmembrane efflux pump, loss of porins, synthesis of antibiotic modifying enzymes, target mutations, ribosomal mutation or modifications, mutations in lipopolysaccharide structure etc. these organisms have developed drug-resistant property and the genes encoded in plasmids play a vital role in developing the resistant. Among all Gram-negative bacteria, Acinetobacter baumannii is an emerging pathogen that accounts for about 80% of all reported infections. Although other species of Acinetobacter are also often associated with HAIs. Acinetobacter is non-motile, obligate aerobic Gram-negative coccobacillus and are ubiquitous free-living saprophytes in soil and water. It is commonly transmitted through medical devices such as ventilators, urinary catheters and other invasive devices in hospitals but its ability to colonize on the skin of individuals often increases the rate of transmission through person to person contact. Patients admitted to Intensive Care Unit (ICU) are at the major risk of getting infected by A. baumannii and these includes pneumonia/ ventilator associated pneumonia
(VAP), bloodstream infections, wound abscesses, urinary tract infections etc.



Download data is not yet available.


Ducel G, Fabry J, Nicolle L. Guide Pratique Pour la Lute Contre l’ Infection Hospitalière. WHO/BAC/79.1. Geneva: WHO; 2002.

Benenson AS. Control of Communicable Diseases Manual. 16th ed. Washington, DC: American Public Health Association; 1995.

Ponce de Leon S. The needs of developing countries and the resources required. J Hosp Infect 1991;18:376-81.

Ducel G, Fabry J, Nicolle L, editors. Prevention of Hospital-Acquired Infections. A Practical Guide. 2nd ed. WHO/CDS/CSR/EPH/2002.12. Geneva: World Health Organization.

Health Care - Associated Infections. World Health Organisation. Available from: fact_sheet_en.pdf.

Falagas ME, Karveli EA, Siempos II, Vardakas KZ. Acinetobacter infections: A growing threat for critically ill patients. Epidemiol Infect 2008;136(8):1009-19.

Beijerinck M. Pigmenten als oxydatieproducten gevormd door bacterien. Ver K Akad Wet Amst 1911;19:1092-103.

Brisou J, Prevot AR. Studies on bacterial taxonomy. X. The revision of species under Achromobacter group. Ann Inst Pasteur (Paris) 1954;86(6):722-8.

Rossau R, van Landschoot A, Gillis M, de Ley J. Taxonomy of Moraxellaceae fam. nov., a new bacterial family to accommodate the genera Moraxella, Acinetobacter, and Psychrobacter and related organisms. Int J Syst Bacteriol 1991;41:310-9.

Skerman VB, McGowan V, Sneath PH. Approved list of bacterial names. Int J Syst Bacteriol 1980;30:225-420.

Allen DM, Hartman BJ. Acinetobacter species. In: Mandell GL,Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th ed., Vol. 2. Philadelphia: Churchill Livingstone; 2000. p. 2239-44.

Bergogne-Berezin E, Towner KJ. Acinetobacter as nosocomial pathogens: Microbiological, clinical and epidemiological features. Clin Microbiol Rev 1996;9:148-65.

Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. Distribution of Acinetobacter species on human skin: Comparison of phenotypic and genotypic identification methods. J Clin Microbiol 1997;35(11):2819-25.

La Scola B, Raoult D. Acinetobacter baumannii in human body louse. Emerg Infect Dis 2004;10(9):1671-3.

Dijkshoorn L, van Aken E, Shunburne L, van der Reijden TJ, Bernards AT, Nemec A, et al. Prevalence of Acinetobacter baumannii and other Acinetobacter spp. in faecal samples from non-hospitalised individuals. Clin Microbiol Infect 2005;11(4):329-32.

Chu YW, Leung CM, Houang ET, Ng KC, Leung CB, Leung HY, et al. Skin carriage of Acinetobacters in Hong Kong. J Clin Microbiol 1999;37(9):2962-7.

Berlau J, Aucken HM, Houang E, Pitt TL. Isolation of Acinetobacter spp. including A. baumannii from vegetables: Implications for hospitalacquired infections. J Hosp Infect 1999;42:201-4.

Houang ET, Chu TW, Leung CM, Chu KY, Berlau J, Ng KC, et al. Epidemiology and infection control implications of Acinetobacter spp. in Hong Kong. J Clin Microbiol 2001;39:228-34.

Weernink A, Severin WP, Tjernberg I, Dijkshoorn L. Pillows, an unexpected source of Acinetobacter. J Hosp Infect 1995;29(3):189-99.

Nagler A, Pavel L, Naparstek E, Muggia-Sullam M, Slavin S. Typhlitis occurring in autologous bone marrow transplantation. Bone Marrow Transplant 1992;9(1):63-4.

Getchell-White SI, Donowitz LG, Gröschel DH. The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: Evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol 1989;10(9):402-7.

Allen KD, Green HT. Hospital outbreak of multi-resistant Acinetobacter

anitratus: An airborne mode of spread? J Hosp Infect 1987;9(2):110-9.

Abrutyn E, Goodhart GL, Roos K, Anderson R, Buxton A. Acinetobacter calcoaceticus outbreak associated with peritoneal dialysis. Am J Epidemiol 1978;107(4):328-35.

Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol 1991;29(2):277-82.

Kämpfer P, Tjernberg I, Ursing J. Numerical classification and identification of Acinetobacter genomic species. J Appl Bacteriol 1993;75(5):259-68.

Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007;13(1):97-103.

Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995;74(6):340-9.

Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007;59(3):525-30.

Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis 2006;43(3):389.

Lee NY, Lee HC, Ko NY, Chang CM, Shih HI, Wu CJ, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007;28(6):713-9.

Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007;26(11):793-800.

Albrecht MC, Griffith ME, Murray CK, Chung KK, Horvath EE, Ward JA, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg 2006;203(4):546-50.

Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: A matched cohort study. Intensive Care Med 2003;29(3):471-5.

Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42(5):692-9.

Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol


Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43 Suppl 2:S49-56.

Thomson JM, Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: Beta-lactams in peril! Curr Opin Microbiol 2005;8(5):518-24.

Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005;25(1):11-25.

Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006;2(1):e7.

Gales AC, Pfaller MA, Sader HS, Hollis RJ, Jones RN. Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp.isolated in Latin America. Microb Drug Resist 2004;10(4):286-91.

Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 2005;11(8):1218-24.

Pooja BM, Sweta RS, Sheela DK, Dileep VK. Characterization of carbapenem resistant Acinetobacter baumannii isolated in a tertiary care hospital: Epidemiology and treatment outcome. Int J Pharm Pharm Sci 2016;8(7):277-81.

Rabadia A, Kamat SD, Kamat DV. Study of synergistic action of cefotaxime and Terminalia chebula on Acinetobacter baumannii using checkerboard assay. Int J Pharm Pharm Sci 2013;5(3):830-2.



How to Cite

Nandi, D., and A. Arjuna. “ACINETOBACTER MAIN CAUSE OF HOSPITAL ACQUIRED INFECTIONS: A REVIEW”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 5, May 2017, pp. 53-56, doi:10.22159/ajpcr.2017.v10i5.17511.



Review Article(s)